Soluble tumor necrosis factor receptor prevents post-pump syndrome

被引:28
|
作者
Carney, DE
Lutz, CJ
Picone, AL
Gatto, LA
Schiller, HJ
Finck, CM
Searles, B
Paskanik, AM
Snyder, KP
Edwards, C
Nieman, GF
机构
[1] SUNY Hlth Sci Ctr, Dept Surg, Syracuse, NY 13210 USA
[2] SUNY Hlth Sci Ctr, Dept Cardiovasc Perfus, Syracuse, NY 13210 USA
[3] Amgen Inc, Boulder, CO USA
关键词
cardiopulmonary bypass; ARDS; acute lung injury; tumor necrosis factor (TNF); soluble tumor necrosis factor-binding protein (TNFbp);
D O I
10.1006/jsre.1999.5576
中图分类号
R61 [外科手术学];
学科分类号
摘要
Post-pump syndrome is an acute lung injury following cardiopulmonary bypass (CPB) which is indistinguishable from the adult respiratory distress syndrome (ARDS), Tumor necrosis factor (TNF) is central to the inflammatory process and is capable of triggering the entire pathophysiologic response leading to ARDS. We hypothesized that treatment with a soluble TNF receptor-binding protein (TNFbp) would reduce the increase in serum TNF and prevent acute lung injury in our sequential insult model of ARDS following CPB, Anesthetized pigs were randomized to one of three groups: Control (n = 3), surgical preparation only; CPB + LPS (n = 6), femoral-femoral hypothermic bypass for 1 h followed by infusion of low dose Escherichia coli lipopolysaccharide (LPS; 1 mu g/kg); and TNFbp + CPB + LPS (n = 4), pretreatment with intravenous TNFbp (2 mg/kg) followed immediately by both insults. CPB + LPS caused severe lung injury demonstrated by a significant fall in PaO2 and an increase in both intrapulmonary shunt and peak airway pressure as compared to all groups (P < 0.05), These changes were associated with a significant increase in plasma TNF level and pulmonary neutrophil sequestration. TNFbp significantly reduced plasma levels of TNF and prevented the lung injury typically observed with this ARDS model, but did not reduce pulmonary neutrophil sequestration. Thus, elevated serum TNF is not responsible for neutrophil sequestration but does play a role in neutrophil activation which causes lung injury. Prophylactic use of TNFbp in CPB patients may prevent neutrophil activation and reduce the incidence of post-pump ARDS. (C) 1999 Academic Press.
引用
收藏
页码:113 / 121
页数:9
相关论文
共 50 条
  • [31] Serum Soluble Tumor Necrosis Factor Receptor (sTNFR) 1 and 2 in STEMI
    Bochaton, Thomas
    Paccalet, Alexandre
    Da Silva, Claire Crola
    Mechtouff, Laura
    Baetz, Delphine
    Jossan, Claire
    Amaz, Camille
    Fiard, Guillaume
    Cartier, Regine
    Tomasevic, Danka
    Prieur, Cyril
    Genot, Nathalie
    Bernelin, Hugo
    Rioufol, Gilles
    Bonnefoy-Cudraz, Eric
    Mewton, Nathan
    Ovize, Michel
    CIRCULATION, 2019, 140
  • [32] The tumor necrosis factor α and its soluble receptor profile in term and preterm parturition
    Maymon, E
    Ghezzi, F
    Edwin, SS
    Mazor, M
    Yoon, BH
    Gomez, R
    Romero, R
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 181 (05) : 1142 - 1148
  • [33] Soluble tumor necrosis factor receptor-I in preterm infants with chorioamnionitis
    Sato, Miho
    Nishimaki, Shigeru
    An, Hiromi
    Shima, Yoshio
    Naruto, Takuya
    Sugai, Toshiyuki
    Iwasaki, Shiho
    Seki, Kazuo
    Imagawa, Tomoyuki
    Mori, Masaaki
    Yokota, Shumpei
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2009, 35 (02) : 252 - 257
  • [34] Expression of soluble human tumor necrosis factor receptor I in Aspergillus niger
    Li, M
    Hong, B
    Li, Y
    CHINESE SCIENCE BULLETIN, 2001, 46 (11): : 918 - 921
  • [35] Cytokine expression in otitis media with effusion - Tumor necrosis factor soluble receptor
    Maxwell, K
    Leonard, G
    Kreutzer, DL
    ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 1997, 123 (09) : 984 - 988
  • [36] Reducing the post-pump syndrome by using heparin-coated circuits, steroids, or aprotinin
    Harig, F
    Feyrer, R
    Mahmoud, FO
    Blum, U
    von der Emde, J
    THORACIC AND CARDIOVASCULAR SURGEON, 1999, 47 (02): : 111 - 118
  • [37] Soluble tumor necrosis factor receptor type I enhances tumor development and persistence in vivo
    Selinsky, CL
    Howell, MD
    CELLULAR IMMUNOLOGY, 2000, 200 (02) : 81 - 87
  • [38] Soluble Tumor Necrosis Factor Receptor shed by breast tumor cells modulates macrophage migration
    Rego, Stephen
    Ricci, Krista
    Swamydas, Muthulekha
    Dreau, Didier
    CANCER RESEARCH, 2012, 72
  • [39] Development of a baculovirus expression system for soluble porcine tumor necrosis factor receptor type I and soluble porcine tumor necrosis factor receptor type I-IgG fusion protein
    Mwangi, SM
    Stabel, TJ
    Kehrli, ME
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2002, 86 (3-4) : 251 - 254
  • [40] SOLUBLE HUMAN-COMPLEMENT RECEPTOR AND TUMOR-NECROSIS-FACTOR RECEPTOR AS ANTIINFLAMMATORY AGENTS
    WARD, PA
    MULLIGAN, MS
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1993, 206 : 254 - MEDI